|Bid||2.3800 x 3100|
|Ask||2.6300 x 1100|
|Day's Range||2.3600 - 2.6100|
|52 Week Range||1.7400 - 5.7500|
|Beta (5Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 21, 2021 - Jul 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.68|
Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months Two of seven CPI-refractory patients experienced stable disease for up to 10 months after initial GEN-009 vaccination In the monotherapy cohort, six of eight patients with no measurable disease continue without recurrence for a median duration of 25 months after initial GEN-009 vaccination Augmented T cell
A look at the shareholders of Genocea Biosciences, Inc. ( NASDAQ:GNCA ) can tell us which group is most powerful...
Genocea Biosciences (GNCA) delivered earnings and revenue surprises of 15.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?